Audit: QRS - Tocopherols for Health & Longevity

Audit conducted on 11/08/2026 18:47 using AI4L / Grok 4

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Claims in At-a-Glance, Protocol, Benefits, Risks, Gates, Monitoring, and Qualitative map to ER Conclusion, Protocol, Expected Benefits, Potential Risks, Key Interactions & Contraindications, and Monitoring.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Preserves “Possible” on all-cause mortality; Speculative tier for longevity and γ-tocopherol displacement.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications from Populations who should avoid; interactions from Key Interactions bullets; benefits/risks keep ER tiers.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	SELECT appears only in PSA why-text, matching ER Monitoring table.
1.6	The QRS does not introduce new attributions.	🟢

---

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	At-a-Glance uses fatty liver, nerve damage, bleeding-type stroke; technical terms retained where they are ER labels or biomarkers.
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Emphasizes food-first / low-dose over casual high-dose prevention; disease-specific medium benefits retained.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢

---

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All template variable spans present; marker_# / qualitative_item_# expanded to concrete indices.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢

---

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No empty ER source sections requiring empty-state phrasing.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Qualitative Assessment and biomarker names match ER Monitoring labels; Protocol uses Dose/Form/Timing action labels as designed by the QRS structure.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Content condensed to single-sheet structure with standard section budgets.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	duration quoted as “00:02” because of colon; other values unquoted and trimmed.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: tocopherols_2026-0811-1356_Grok_ER.md
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0811-1737
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Grok
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Grok 4
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	tocopherols_2026-0811-1356_Grok_QRS.html
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

---

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Tocopherols for Health & Longevity - Quick Reference Sheet
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Tocopherols for Health & Longevity
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	08/11/2026 from 2026-0811-1737
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Grok 4
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

---

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢
7.2	[at_a_glance] is no longer than 60 words	🟢	Exactly 60 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Deficiency role, selective NASH/AD benefits, prevention nulls and harms, food-first preference all in Conclusion / Practical / Benefits / Risks.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Uses nerve damage, fatty liver, bleeding-type stroke, day-to-day function.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

---

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢	Four populations who should avoid high-dose/preventive use; dietary repletion exclusion not listed as a stop item (correct).
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Preserves ≥400 IU/day thresholds and high-dose context.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER does not use ranking notation in contraindication items.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	Section populated; ER lists avoid populations.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty.

---

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Six interactions listed; chemotherapy/radiotherapy excluded because already covered under Contraindications.
9.3	Individual [caution_items] are formatted as <li></li>	🟢
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Trailing Caution/Monitor elaborations stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	e.g., apixaban, clopidogrel + aspirin preserved.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER does not use ranking notation in interaction items.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	Section populated with interactions.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty.

---

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose (~15 mg RDA / 15–100 mg if supplementing), Form (mixed/RRR vs synthetic), Timing (with fat meal).
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct aspects are present and filled.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢

---

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Deficiency neurology, fatty-liver enzymes, Alzheimer function from Practical Considerations.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	High-tier deficiency first, then medium NASH enzymes, then medium AD function.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three time-to-effect aspects are present.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	ER provides time-to-effect information; section retained.

---

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers have items.

---

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers have items.

---

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All seven table biomarkers present: serum α-tocopherol, lipid ratio, ALT, AST, INR, CBC/platelets, PSA.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Matches ER 8–12 week recheck, 6–12 month ongoing, INR 1–2 weeks, ALT/AST 3–6 months.

---

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All four: neurologic symptoms, energy/training, bruising/bleeding, cognitive/functional AD metrics.

Issues 11/08/2026 18:47

Pass rate 100.00%. No issues found.

Issues 11/08/2026 18:40

1. 1.1 — Invented food RDA label: action_1_value uses “food RDA” (lines 447–448), which is not an ER term; ER states ~15 mg/day α-tocopherol equivalents (adult RDA) from food.

2. 1.3 / 2.5 — Normative favored phrasing: at_a_glance ends with “are favored over casual high-dose use” (line 433), converting ER Conclusion “evidence favors …” into a bare preference/recommendation rather than presenting the evidence stance.

Fixes 11/08/2026 18:40

1. 1.1 — Invented food RDA label: Changed action_1_value from “~15 mg/day (food RDA)” to “~15 mg/day (adult RDA)” to match ER dietary baseline wording.

2. 1.3 / 2.5 — Normative favored phrasing: Rewrote at_a_glance closing clause from “Food-first intake … are favored over …” to “Evidence favors food-first intake … over …” so the sentence presents the ER Conclusion stance rather than a bare preference (still 60 words).

Issues 11/08/2026 18:28

1. 1.2 — Cautious phrasing dropped: time_2_sub omits ER “may appear” for fatty-liver enzyme timing; qualitative_item_2 drops “Watch for”/”may blunt” wording from Monitoring/Exercise.

2. 1.3 — Claims strengthened: Same fields present liver-enzyme change and training blunting as definite rather than possible/typical caveats from the ER.

Fixes 11/08/2026 18:31

1. 1.2 — Cautious phrasing restored: Updated time_2_sub to “Liver enzyme changes may appear…” and qualitative_item_2 to “Possible blunted adaptation…” to match ER wording.

2. 1.3 — Strengthened claims softened: Same two fields no longer present enzyme change or training blunting as definite outcomes.

Issues 11/08/2026 18:19

1. 1.2 — Cautious mortality phrasing lost: At-a-glance groups all-cause mortality with other harms as undifferentiated “signals,” dropping the ER’s “Possible increase” caution from the medium-risk mortality finding.

2. 1.3 — Softened deficiency and cancer claims: At-a-glance narrows ER “prevention and treatment” of deficiency to “treating” only, and softens SELECT’s increased prostate cancer finding into a generic “signal.”

3. 7.4 — Clinical register in at-a-glance: Uses “neurologic injury,” “hemorrhagic stroke,” and “heart-failure signals” rather than plain-language equivalents.

Fixes 11/08/2026 18:22

1. 1.2 — Cautious mortality phrasing: Restored “possible higher death rates” in at-a-glance so mortality keeps the ER’s cautious medium-risk framing instead of an undifferentiated “signals” bundle.

2. 1.3 — Deficiency and cancer strength: Rewrote at-a-glance to “preventing and treating” deficiency (matching ER Conclusion) and “raised prostate cancer risk” rather than a softened generic signal.

3. 7.4 — Plain-language at-a-glance: Replaced “neurologic injury,” “hemorrhagic stroke,” and “heart-failure signals” with “nerve damage,” “bleeding-type stroke,” and “heart-failure risk” (60 words).

Issues 11/08/2026 18:12

1. 2.6 / 2.9 — Direct reader address: qualitative_item_2 uses imperative “Watch for blunted adaptation if high-dosing during heavy training blocks”, addressing the reader rather than only presenting evidence.
2. 9.4 — Study detail in interaction: caution_items includes “Statins and niacin (historical simvastatin–niacin trials)”; the parenthetical is study detail that 9.4 requires stripped (keep “Statins and niacin”).

Fixes 11/08/2026 18:12

1. 2.6 / 2.9 — Direct reader address: Rewrote qualitative_item_2 from imperative “Watch for blunted adaptation…” to “Blunted adaptation if high-dosing during heavy training blocks” so the sheet presents the signal without addressing the reader.
2. 9.4 — Study detail in interaction: Stripped the study-detail parenthetical from the Key Interactions item, leaving “Statins and niacin”.

Issues 11/08/2026 18:03

1. 1.1 / 12.3 — AMD benefit wording: benefits_low says “Age-related macular degeneration progression as part of AREDS formula,” which drops the reduced-progression direction and includes the AREDS study name (lines 528–529).
2. 1.3 / 2.5 — Protocol advisory verbs: action_1_sub uses “avoid ≥400 IU…” and action_2_sub uses “Prefer d-α / mixed…” instead of presentational ER-aligned phrasing (lines 450–461).
3. 2.7 — NASH unexpanded: time_2_label “NASH enzymes” and time_2_sub use “NASH” before any expansion; full term appears only later in Benefits (lines 504–500).

Fixes 11/08/2026 18:05

1. 1.1 / 12.3 — AMD benefit wording: Rewrote benefits_low to “Slower age-related macular degeneration progression with combination formula” (removed AREDS study name; restored reduced-progression direction).
2. 1.3 / 2.5 — Protocol advisory verbs: Replaced “avoid ≥400 IU…” with “rather than ≥400 IU…” in action_1_sub; removed leading “Prefer” from action_2_sub so form comparison is presentational.
3. 2.7 — NASH unexpanded: Replaced first-use “NASH” in time_2_label/sub with “Fatty-liver enzymes” / “steatohepatitis protocols”; aligned marker_3_why and monitoring_cadence to “steatohepatitis protocols”.

Issues 11/08/2026 17:58

1. 1.1 — Unsupported synthetic-harm grouping / AMD scope: At-a-glance groups mortality, bleeding stroke, and heart-failure under “high-dose synthetic forms,” but HOPE/HOPE-TOO heart failure used natural vitamin E and Miller/Schürks are not synthetic-only; Low Benefits states AMD progression without the ER’s AREDS-combination limitation.
2. 1.3 — Softened harms / strengthened AMD: At-a-glance softens ER harm findings to “concerns”; AMD benefit omits AREDS-only scope and overstates tocopherol-alone support.
3. 2.15 — Colloquial stroke wording: At-a-glance uses “bleeding stroke” instead of formal “hemorrhagic stroke.”
4. 7.3 — At-a-glance fact not ER-supported: The synthetic-forms attribution for HF/mortality/stroke in at-a-glance is not backed by distinct ER passages.

Fixes 11/08/2026 18:00

1. 1.1 / 7.3 — At-a-glance harm attribution: Rewrote at-a-glance to drop the incorrect “synthetic forms” grouping for mortality, stroke, and heart-failure signals; uses “High-dose prevention” and “signals” aligned with the ER.
2. 1.3 — AMD benefit scope / harm tone: Added “as part of AREDS formula” to the Low AMD benefit (non-parenthetical) so the claim is not strengthened beyond the ER; replaced soft “concerns” with “signals” in at-a-glance.
3. 2.15 — Hemorrhagic stroke wording: Replaced colloquial “bleeding stroke” with formal “hemorrhagic stroke” in at-a-glance.
4. 1.1 — Neurologic injury wording: Restored “neurologic injury” (ER term) in place of abbreviated “nerve injury” in at-a-glance.

Issues 11/08/2026 17:51

1. 4.2 — Non-verbatim ER labels: Key Interactions and Qualitative Assessment reuse ER **Label:** items but paraphrase several labels instead of copying them verbatim (statins/niacin parenthetical, orlistat order, mixed-antioxidant wording, and qualitative symptom labels).
2. 4.3 — Paraphrased labels: Same labels are paraphrased, abbreviated, or reordered rather than kept as in the ER.

Fixes 11/08/2026 17:53

1. 4.2 / 4.3 — Verbatim interaction labels: Restored ER bold labels for Key Interactions: “Statins and niacin (historical simvastatin–niacin trials)”, “Other fat-soluble vitamins and orlistat / bile-acid binders”, and “Mixed antioxidant "cocktails" at high dose”.
2. 4.2 / 4.3 — Verbatim qualitative labels: Restored ER bold labels and content wording for Qualitative Assessment items: “Neurologic symptoms (deficiency)”, “Bruising / bleeding / stool color”, and “Cognitive/functional AD metrics” (with ADLs).

Issues 11/08/2026 17:42

1. 1.3 — Strengthened conclusion phrasing: At-a-glance “beat casual high-dose supplements” strengthens the ER Conclusion’s “evidence favors … over open-ended high-dose α-only supplements.”
2. 2.15 — Colloquial “beat”: Same at-a-glance clause uses consumer-grade “beat” instead of formal clinical phrasing.
3. 9.2 — Chemo listed twice: Chemotherapy/radiotherapy appears in both Contraindications and Key Interactions; 9.2 requires excluding interactions already listed as contraindications.
4. 12.3 — Low-tier qualifiers retained: benefits_low keeps “Modest support” and “as part of AREDS formula” rather than the bare key fact only.
5. 12.4 — AREDS parenthetical kept: ER parenthetical “(as Part of AREDS Formula)” was not stripped from benefits_low.

Fixes 11/08/2026 17:44

1. 1.3 / 2.15 — At-a-glance closing tone: Replaced colloquial “beat casual high-dose supplements” with formal “are favored over casual high-dose supplements,” matching the ER Conclusion without strengthening the claim.
2. 9.2 — Duplicate chemo interaction: Removed “Chemotherapy and radiotherapy (high-dose antioxidants)” from Key Interactions because the same exposure is already listed under Contraindications.
3. 12.3 / 12.4 — Low-tier benefit wording: Stripped “Modest support,” “as part of AREDS formula,” and “in supplemental trials” from benefits_low, leaving “Age-related macular degeneration progression; Endothelial function and C-reactive protein.”